Off-label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VII

This publication has 18 references indexed in Scilit:

• Use of Recombinant Activated Factor VII (Novoseven) in Trauma and Surgery: Analysis of Outcomes Reported to an International Registry
  Journal of Intensive Care Medicine, 2006
• Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation
  Journal of Thrombosis and Haemostasis, 2005
• Nesiritide — Not Verified
  New England Journal of Medicine, 2005
• Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials
  Published by Wolters Kluwer Health ,2005
• Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial † †This article is accompanied by the Editorial. ‡ ‡Declaration of interest. R. M. Grounds has worked in the past as a consultant for Novo Nordisk and has lectured at symposiums organized by Novo Nordisk. Novo Nordisk has given an unrestricted educational grant to St George’s Hospital Special Trustee’s. The trial was funded by Novo Nordisk, UK.
  British Journal of Anaesthesia, 2005
• Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
  New England Journal of Medicine, 2005
• Stopping the Bleeding in Intracerebral Hemorrhage
  New England Journal of Medicine, 2005
• Recombinant Coagulation Factor VIIa in Major Liver Resection
  Anesthesiology, 2005
• EFFICACY AND SAFETY OF RECOMBINANT FACTOR VIIa (rFVIIa) ON TRANSFUSION REDUCTION IN ORTHOTOPIC LIVER TRANSPLANTATION (OLT) – A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
  Transplantation, 2004
• Pfizer pleads guilty, but drug sales continue to soar
  BMJ, 2004